Business
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ: TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its US network of healthcare institutions. Eligible patients have type 2 diabetes with chronic kidney disease, impacting nearly 15 million individuals in the US.
About this update from Renalytix Plc
[{"type":"text","content":"Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes","length":182,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ: TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its US network of healthcare institutions. Eligible patients have type 2 diabetes with chronic kidney disease, impacting nearly 15 million individuals in the US.","length":419,"tagName":"p"},{"type":"image","alt":"Renalytix plc (PRNewsfoto/Renalytix plc)","displaySize":"","headline":null,"caption":"Renalytix plc (PRNewsfoto/Renalytix plc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":163,"url":"https://media.zenfs.com/en/prnewswire.com/cd4b47f5a3572d110efdddaf25f72e5d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p9RQP3geLZCAzkHTvsMASA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/cd4b47f5a3572d110efdddaf25f72e5d","width":400,"height":163}},"href":"https://mma.prnewswire.com/media/2562585/Renalytix_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Renalytix's kidneyintelX.dkd will be the first test offered in Tempus' portfolio in the chronic kidney disease category, indicated for use as an aid in predicting level of risk (high, moderate, low) for progressive decline in kidney function in type 2 diabetes patients with diagnosed chronic kidney disease stages 1-3b.","length":328,"tagName":"p"},{"type":"text","content":""The unique Tempus platform, with its broad clinical reach, will allow us to significantly expand patient and clinician access to advance kidneyintelX.dkd precision medicine testing in one of the largest and costliest chronic disease conditions today," said James McCullough, CEO Renalytix. "Further, we expect our partnership to be instrumental in driving therapeutic and diagnostic innovation through multi-modal data accumulation and analysis in patients in the cardiovascular, renal and metabolic space." ","length":533,"tagName":"p"},{"type":"text","content":""...